Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations.

Evans AH, Okai D, Weintraub D, Lim SY, O'Sullivan SS, Voon V, Krack P, Sampaio C, Post B, Leentjens AFG, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A; Members of the International Parkinson and Movement Disorder Society (IPMDS) Rating Scales Review Committee.

Mov Disord. 2019 Jun;34(6):791-798. doi: 10.1002/mds.27689. Epub 2019 May 28. Review.

PMID:
31136681
2.

Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease.

Espay AJ, Foster ED, Coffey CS, Uribe L, Caspell-Garcia CJ, Weintraub D; Parkinson's Progression Markers Initiative.

J Neurol Sci. 2019 Jul 15;402:81-85. doi: 10.1016/j.jns.2019.05.009. Epub 2019 May 16.

PMID:
31125734
3.

Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression.

Pereira JB, Weintraub D, Chahine L, Aarsland D, Hansson O, Westman E.

NPJ Parkinsons Dis. 2019 May 3;5:7. doi: 10.1038/s41531-019-0079-3. eCollection 2019.

4.

Altered large-scale functional brain networks in neurological Wilson's disease.

Jing R, Han Y, Cheng H, Han Y, Wang K, Weintraub D, Fan Y.

Brain Imaging Behav. 2019 Apr 22. doi: 10.1007/s11682-019-00066-y. [Epub ahead of print]

PMID:
31011947
5.

The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

Weintraub D, Mamikonyan E.

Am J Geriatr Psychiatry. 2019 Mar 9. pii: S1064-7481(19)30281-7. doi: 10.1016/j.jagp.2019.03.002. [Epub ahead of print] Review.

PMID:
31006550
6.

TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia.

Tropea TF, Mak J, Guo MH, Xie SX, Suh E, Rick J, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Trojanowski JQ, Van Deerlin V, Chen-Plotkin AS.

Ann Neurol. 2019 Jun;85(6):801-811. doi: 10.1002/ana.25486.

PMID:
30973966
7.

Integration and Extension of Specialty Mental Healthcare Services to Community Practice in Parkinson Disease.

Pontone GM, Dissanayaka N, Dobkin RD, Mari L, Marsh L, Vernaleo BA, Weintraub D, Mari Z.

Am J Geriatr Psychiatry. 2019 Jul;27(7):712-719. doi: 10.1016/j.jagp.2019.03.005. Epub 2019 Mar 13.

PMID:
30955991
8.

Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS).

Martinez-Martin P, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Chaudhuri KR; IPMDS Non Motor PD Study Group.

Mov Disord Clin Pract. 2019 Feb 5;6(3):227-234. doi: 10.1002/mdc3.12728. eCollection 2019 Mar.

PMID:
30949554
9.

Impulse control disorders in Parkinson's disease: A 20-year odyssey.

Weintraub D.

Mov Disord. 2019 Apr;34(4):447-452. doi: 10.1002/mds.27668. Epub 2019 Mar 26. No abstract available.

PMID:
30913337
10.

French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS).

Marques A, Vidal T, Pereira B, Benchetrit E, Socha J, Pineau F, Elbaz A, Artaud F, Mangone G, You H, Cormier F, Galitstky M, Pomies E, Rascol O, Derkinderen P, Weintraub D, Corvol JC, Durif F; DIGPD study group.

Parkinsonism Relat Disord. 2019 Mar 4. pii: S1353-8020(19)30072-0. doi: 10.1016/j.parkreldis.2019.02.026. [Epub ahead of print]

PMID:
30862454
11.

Impulse Control Disorders in Parkinson's Disease.

Weintraub D, Mamikonyan E.

Am J Psychiatry. 2019 Jan 1;176(1):5-11. doi: 10.1176/appi.ajp.2018.18040465. No abstract available.

PMID:
30848949
12.

Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Frank S, Jennings D, Simuni T; Parkinson's Progression Markers InitiativeSteering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board.

Parkinsonism Relat Disord. 2019 May;62:201-209. doi: 10.1016/j.parkreldis.2018.12.025. Epub 2019 Jan 31.

PMID:
30738748
13.

Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis.

Barman SA, Li X, Haigh S, Kondrikov D, Mahboubi K, Bordan Z, Stepp DW, Zhou J, Wang Y, Weintraub DS, Traber P, Snider W, Jonigk D, Sullivan J, Crislip GR, Butcher JT, Thompson J, Su Y, Chen F, Fulton DJR.

Am J Physiol Lung Cell Mol Physiol. 2019 May 1;316(5):L784-L797. doi: 10.1152/ajplung.00186.2018. Epub 2019 Feb 6.

PMID:
30724100
14.

Risk of Parkinson's disease dementia related to level I MDS PD-MCI.

Hoogland J, Boel JA, de Bie RMA, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2019 Mar;34(3):430-435. doi: 10.1002/mds.27617. Epub 2019 Jan 17.

PMID:
30653248
15.

Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.

Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee.

Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Review. Erratum in: Mov Disord. 2019 May;34(5):765.

PMID:
30653247
16.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T; Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.

17.

Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.

Coughlin D, Xie SX, Liang M, Williams A, Peterson C, Weintraub D, McMillan CT, Wolk DA, Akhtar RS, Hurtig HI, Branch Coslett H, Hamilton RH, Siderowf AD, Duda JE, Rascovsky K, Lee EB, Lee VM, Grossman M, Trojanowski JQ, Irwin DJ.

Ann Neurol. 2019 Feb;85(2):259-271. doi: 10.1002/ana.25392. Epub 2019 Jan 7.

18.

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.

Olsson B, Portelius E, Cullen NC, Sandelius Å, Zetterberg H, Andreasson U, Höglund K, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk D, McCluskey L, Elman L, Shaw LM, Toledo JB, McBride J, Hernandez-Con P, Lee VM, Trojanowski JQ, Blennow K.

JAMA Neurol. 2018 Dec 3. doi: 10.1001/jamaneurol.2018.3746. [Epub ahead of print]

PMID:
30508027
19.

Stimulus-based and task-based attention modulate auditory stream segregation context effects.

Yerkes BD, Weintraub DM, Snyder JS.

J Exp Psychol Hum Percept Perform. 2019 Jan;45(1):53-66. doi: 10.1037/xhp0000587. Epub 2018 Nov 26.

PMID:
30475025
20.

Pharmacological treatment of apathy in Lewy body disorders: A systematic review.

Liu J, Cooper CA, Weintraub D, Dahodwala N.

Parkinsonism Relat Disord. 2019 Mar;60:14-24. doi: 10.1016/j.parkreldis.2018.11.002. Epub 2018 Nov 5. Review.

PMID:
30470658
21.

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.

Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, Factor SA, Friedman JH, Lang AE, Larsen NJ, Andersson C, Fredericks D, Weintraub D.

Mov Disord. 2018 Nov;33(11):1769-1776. doi: 10.1002/mds.27488. Epub 2018 Nov 2.

PMID:
30387904
22.

Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology.

Sandelius Å, Portelius E, Källén Å, Zetterberg H, Rot U, Olsson B, Toledo JB, Shaw LM, Lee VMY, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk DA, McCluskey L, Elman L, Kostanjevecki V, Vandijck M, McBride J, Trojanowski JQ, Blennow K.

Alzheimers Dement. 2019 Jan;15(1):55-64. doi: 10.1016/j.jalz.2018.08.006. Epub 2018 Oct 12.

23.

Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease.

Holden SK, Medina LD, Hoyt B, Sillau SH, Berman BD, Goldman JG, Weintraub D, Kluger BM.

Mov Disord. 2018 Nov;33(11):1760-1768. doi: 10.1002/mds.27487. Epub 2018 Oct 10.

PMID:
30306618
24.

Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease.

Mantri S, Fullard M, Gray SL, Weintraub D, Hubbard RA, Hennessy S, Willis AW.

JAMA Neurol. 2019 Jan 1;76(1):41-49. doi: 10.1001/jamaneurol.2018.2820.

PMID:
30285047
25.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14.

PMID:
30216541
26.

Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease.

Chahine LM, Dos Santos C, Fullard M, Scordia C, Weintraub D, Erus G, Rosenthal L, Davatzikos C, McMillan CT.

Eur J Neurol. 2019 Feb;26(2):246-e18. doi: 10.1111/ene.13797. Epub 2018 Oct 28.

PMID:
30169897
27.

Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder.

Kamps S, van den Heuvel OA, van der Werf YD, Berendse HW, Weintraub D, Vriend C.

Brain Imaging Behav. 2018 Aug 28. doi: 10.1007/s11682-018-9939-4. [Epub ahead of print]

PMID:
30155787
28.

Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D; Parkinson’s Progression Markers Initiative.

PLoS One. 2018 Aug 20;13(8):e0201964. doi: 10.1371/journal.pone.0201964. eCollection 2018.

29.

Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.

Tao Y, Peters ME, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Munro CA.

Am J Alzheimers Dis Other Demen. 2018 Nov;33(7):450-457. doi: 10.1177/1533317518783278. Epub 2018 Jul 3.

PMID:
29969907
30.

Immigration Policy: Valuing Children.

Mendoza FS, Cueto V, Lawrence D, Sanders L, Weintraub D.

Acad Pediatr. 2018 Sep - Oct;18(7):723-725. doi: 10.1016/j.acap.2018.06.010. Epub 2018 Jun 30. No abstract available.

PMID:
29966712
31.

Hsp70 Suppresses Mitochondrial Reactive Oxygen Species and Preserves Pulmonary Microvascular Barrier Integrity Following Exposure to Bacterial Toxins.

Li X, Yu Y, Gorshkov B, Haigh S, Bordan Z, Weintraub D, Rudic RD, Chakraborty T, Barman SA, Verin AD, Su Y, Lucas R, Stepp DW, Chen F, Fulton DJR.

Front Immunol. 2018 Jun 12;9:1309. doi: 10.3389/fimmu.2018.01309. eCollection 2018.

32.

Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinson's Disease and Cross-Cultural Comparison.

Bezdicek O, Červenková M, Moore TM, Stepankova Georgi H, Sulc Z, Wolk DA, Weintraub DA, Moberg PJ, Jech R, Kopecek M, Roalf DR.

Assessment. 2018 Jun 1:1073191118778896. doi: 10.1177/1073191118778896. [Epub ahead of print]

PMID:
29929376
33.

Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.

Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, Hurtig HI, Siderowf A, Grossman M, McMillan CT, Miller B, Duda JE, Irwin DJ, Wolk D, Elman L, McCluskey L, Chen-Plotkin A, Weintraub D, Arnold SE, Brettschneider J, Lee VM, Trojanowski JQ.

Brain. 2018 Jul 1;141(7):2181-2193. doi: 10.1093/brain/awy146.

PMID:
29878075
34.

Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson's Disease Patients: A Case-Control Study.

Lo Monaco MR, Petracca M, Weintraub D, Fusco D, Liperoti R, Zuccalà G, La Carpia D, Vetrano DL, Genovese D, Pisciotta MS, Brandi V, Padua L, Imbimbo I, Ricciardi D, Bernabei R, Silveri MC, Laudisio A, Bentivoglio AR.

J Clin Psychiatry. 2018 May/Jun;79(3). pii: 17m11612. doi: 10.4088/JCP.17m11612.

PMID:
29702754
35.

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.

Portelius E, Olsson B, Höglund K, Cullen NC, Kvartsberg H, Andreasson U, Zetterberg H, Sandelius Å, Shaw LM, Lee VMY, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk DA, McCluskey L, Elman L, McBride J, Toledo JB, Trojanowski JQ, Blennow K.

Acta Neuropathol. 2018 Sep;136(3):363-376. doi: 10.1007/s00401-018-1851-x. Epub 2018 Apr 26.

36.

Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease.

Roalf DR, Rupert P, Mechanic-Hamilton D, Brennan L, Duda JE, Weintraub D, Trojanowski JQ, Wolk D, Moberg PJ.

J Neurol. 2018 Jun;265(6):1365-1375. doi: 10.1007/s00415-018-8841-8. Epub 2018 Apr 4.

37.

Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.

Shi M, Tang L, Toledo JB, Ginghina C, Wang H, Aro P, Jensen PH, Weintraub D, Chen-Plotkin AS, Irwin DJ, Grossman M, McCluskey L, Elman LB, Wolk DA, Lee EB, Shaw LM, Trojanowski JQ, Zhang J.

Alzheimers Dement. 2018 Aug;14(8):1052-1062. doi: 10.1016/j.jalz.2018.02.015. Epub 2018 Mar 28.

PMID:
29604263
38.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*.

Mov Disord. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23.

39.

Initial cognitive changes in Parkinson's disease.

Weintraub D, Tröster AI, Marras C, Stebbins G.

Mov Disord. 2018 Apr;33(4):511-519. doi: 10.1002/mds.27330. Epub 2018 Mar 15. Review.

40.

CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.

Irwin DJ, Xie SX, Coughlin D, Nevler N, Akhtar RS, McMillan CT, Lee EB, Wolk DA, Weintraub D, Chen-Plotkin A, Duda JE, Spindler M, Siderowf A, Hurtig HI, Shaw LM, Grossman M, Trojanowski JQ.

Neurology. 2018 Mar 20;90(12):e1038-e1046. doi: 10.1212/WNL.0000000000005166. Epub 2018 Feb 21.

41.

Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P.

Mov Disord. 2018 Mar;33(3):499-500. doi: 10.1002/mds.27339. Epub 2018 Feb 20. No abstract available.

PMID:
29460975
42.

Selection of Normative Group Affects Rates of Mild Cognitive Impairment in Parkinson's Disease.

Wyman-Chick KA, Martin PK, Weintraub D, Sperling SA, Erickson LO, Manning CA, Barrett MJ.

Mov Disord. 2018 May;33(5):839-843. doi: 10.1002/mds.27335. Epub 2018 Feb 14.

43.

At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease.

Weintraub D, Hamilton JL, Eberling J, Litvan I.

Mov Disord. 2018 Apr;33(4):501-502. doi: 10.1002/mds.27310. Epub 2018 Feb 8. No abstract available.

PMID:
29418018
44.

Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test.

Morley JF, Cohen A, Silveira-Moriyama L, Lees AJ, Williams DR, Katzenschlager R, Hawkes C, Shtraks JP, Weintraub D, Doty RL, Duda JE.

NPJ Parkinsons Dis. 2018 Jan 15;4:2. doi: 10.1038/s41531-017-0039-8. eCollection 2018.

45.

Deletion of the Duffy antigen receptor for chemokines (DARC) promotes insulin resistance and adipose tissue inflammation during high fat feeding.

Benson TW, Weintraub DS, Crowe M, Yiew NKH, Popoola O, Pillai A, Joseph J, Archer K, Greenway C, Chatterjee TK, Mintz J, Stepp DW, Stansfield BK, Chen W, Brittain J, Bogdanov VY, Gao Y, Wilson JG, Tang Y, Kim HW, Weintraub NL.

Mol Cell Endocrinol. 2018 Sep 15;473:79-88. doi: 10.1016/j.mce.2018.01.006. Epub 2018 Jan 16.

46.

APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.

Tropea TF, Xie SX, Rick J, Chahine LM, Dahodwala N, Doshi J, Davatzikos C, Shaw LM, Van Deerlin V, Trojanowski JQ, Weintraub D, Chen-Plotkin AS.

Mov Disord. 2018 Feb;33(2):289-297. doi: 10.1002/mds.27204. Epub 2017 Nov 23.

47.

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P; members of the MDS Rating Scales Review Committee.

Mov Disord. 2018 Feb;33(2):208-218. doi: 10.1002/mds.27233. Epub 2017 Nov 23. Review.

PMID:
29168899
48.

Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases.

Sheinerman KS, Toledo JB, Tsivinsky VG, Irwin D, Grossman M, Weintraub D, Hurtig HI, Chen-Plotkin A, Wolk DA, McCluskey LF, Elman LB, Trojanowski JQ, Umansky SR.

Alzheimers Res Ther. 2017 Nov 9;9(1):89. doi: 10.1186/s13195-017-0316-0.

49.

Beyond Impressions: How Altered Shear Stress Connects Hypoxic Signaling to Endothelial Inflammation.

Li X, Weintraub DS, Fulton DJR.

Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):1987-1989. doi: 10.1161/ATVBAHA.117.310149. No abstract available.

50.

Cognition and the course of prodromal Parkinson's disease.

Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D; PARS Investigators.

Mov Disord. 2017 Nov;32(11):1640-1645. doi: 10.1002/mds.27189. Epub 2017 Oct 24.

Supplemental Content

Loading ...
Support Center